IFIT2 and melanoma: In SKCM, low expression levels of IFIT3, similar to IFIT1 and IFIT2, have been found to be correlated with patients’ poor overall survival and DSS and decreased sensitivity of melanoma cells to dasatinib [20] and T-cell killing and apoptosis [21].